AMZN
Amazon.com, Inc.
AMZN has the edge over MNRO overall, supported by lower modeled downside and stronger valuation.
MNRO
Monro, Inc.
MNRO trails on the overall score without a compensating advantage in the available component scores.
AMZN Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Weak | |
| Healthy |
AMZN's revenue, profitability and balance sheet are currently healthy, but its cash flow is weak.
MNRO Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Under pressure | |
| Healthy |
MNRO's balance sheet is currently healthy, and its revenue and profitability are stable, but its cash flow is under pressure.
AMZN PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 22x | $267 | — |
| Forward | 27x | $267 | — |
| Cheap | 34x | $415 | +55% |
| Fair | 60x | $745 | +179% |
| Expensive | 102x | $1,262 | +372% |
Historical ranges are pointers, not guarantees.
AMZN's PE is in its cheap range at 22x, but its recent earnings include one-off gains. On analysts' estimates for next year's earnings, today's price would be 27x.
MNRO PE Valuation
MNRO has no meaningful PE right now: it lost money over the past year.
AMZN Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Strong growth | |
| Growth | |
| Improving | |
| Moderate | |
| Moderate |
AMZN has the edge over MNRO on the outlook, with more favorable earnings and revenue expectations.
MNRO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Stable | |
| Weakening | |
| Limited | |
| High |
Analysts expect MNRO's earnings and profitability to decline, with its revenue holding steady.
AMZN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $9.87 | -20% |
| Q3 2026 | $12.37 | +75% |
| Q2 2026 | $12.43 | +89% |
| Q1 2026 | $8.36 | +36% |
| Q4 2025 | $7.17 | +30% |
| Q3 2025 | $7.08 | +52% |
| Q2 2025 | $6.56 | +57% |
| Q1 2025 | $6.14 | +72% |
| Q4 2024 | $5.53 | +91% |
AMZN has the edge over MNRO on earnings, with more consistent year-over-year improvement.
MNRO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $0.00 | +$0.69 |
| Q2 2026 | $0.23 | +$0.92 |
| Q1 2026 | $0.03 | +$0.25 |
| Q4 2025 | -$0.49 | -177% |
| Q3 2025 | -$0.69 | -179% |
| Q2 2025 | -$0.69 | -163% |
| Q1 2025 | -$0.22 | -119% |
| Q4 2024 | $0.64 | -41% |
MNRO is still losing money, but far less than before: $0.00 per share over the past year, against $0.69 at its worst in mid-2025.
AMZN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $201.9B | +12% |
| Q2 2026 | $200.6B | +20% |
| Q1 2026 | $181.5B | +17% |
| Q4 2025 | $213.4B | +14% |
| Q3 2025 | $180.2B | +13% |
| Q2 2025 | $167.7B | +13% |
| Q1 2025 | $155.7B | +8.6% |
| Q4 2024 | $187.8B | +10% |
AMZN has the edge over MNRO on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 14% | +4.2 points |
| Q2 2026 | 14% | +2.3 points |
| Q1 2026 | 13% | +1.3 points |
| Q4 2025 | 12% | +0.4 points |
| Q3 2025 | 9.7% | -1.3 points |
| Q2 2025 | 11% | +1.5 points |
| Q1 2025 | 12% | +1.1 points |
| Q4 2024 | 11% | +3.5 points |
AMZN has the edge over MNRO on profitability, with a higher operating margin.
MNRO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $283.6M | -1.8% |
| Q2 2026 | $287.1M | -4.6% |
| Q1 2026 | $273.8M | -7.2% |
| Q4 2025 | $293.4M | -4% |
| Q3 2025 | $288.9M | -4.1% |
| Q2 2025 | $301M | +2.7% |
| Q1 2025 | $295M | -4.9% |
| Q4 2024 | $305.8M | -3.7% |
MNRO's revenue has slid since its 2022 peak: $284M last quarter, down 1.8% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 0.9% | -3.5 points |
| Q2 2026 | 1.3% | +3.3 points |
| Q1 2026 | -1.9% | +6.2 points |
| Q4 2025 | 6.3% | +3.1 points |
| Q3 2025 | 4.4% | 0 points |
| Q2 2025 | -2% | -6.5 points |
| Q1 2025 | -8.1% | -11 points |
| Q4 2024 | 3.3% | -3.5 points |
MNRO's operating margin was 0.9% last quarter, down 3.5 points from the same quarter a year ago.
AMZN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$34.8B | -8202% |
| Q2 2026 | -$8.8B | -2757% |
| Q1 2026 | -$18.2B | -$10.2B |
| Q4 2025 | $14.9B | -16% |
| Q3 2025 | $430M | -87% |
| Q2 2025 | $332M | -96% |
| Q1 2025 | -$8B | -297% |
| Q4 2024 | $17.8B | -36% |
AMZN's free cash flow was −$46.9B over the past year, against $10.6B the year before.
MNRO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $28.8M | +8.2% |
| Q2 2026 | -$37.9M | -$28.6M |
| Q1 2026 | $12.4M | -47% |
| Q4 2025 | $9.1M | +15% |
| Q3 2025 | $26.6M | -54% |
| Q2 2025 | -$9.3M | -156% |
| Q1 2025 | $23.2M | +$35.1M |
| Q4 2024 | $7.9M | -73% |
MNRO has the edge over AMZN on cash generation, producing positive trailing cash flow while its opponent burns cash.
AMZN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +26M shares |
| 1 year | +0.8% | +84M shares |
| 3 years | +3.5% | +371M shares |
| 5 years | +6.1% | +629M shares |
| Available history | +8.2% | +829M shares |
AMZN has 10.9B diluted shares, up 0.8% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | — |
| Q4 2022 | — |
| Q3 2022 | — |
| Q2 2022 | $3.3B |
MNRO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.8% | +1.1M shares |
| 1 year | -0.2% | -68K shares |
| 3 years | -3% | -977K shares |
| 5 years | -8% | -2.7M shares |
| Available history | -7.9% | -2.7M shares |
MNRO has the edge over AMZN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q1 2024 | — |
| Q1 2023 | — |
| Q4 2022 | $25.7M |
| Q3 2022 | $54M |
| Q2 2022 | $17.2M |
AMZN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.7x | Very low |
| Q2 2026 | 0.3x | Very low |
| Q1 2026 | 0.1x | Very low |
| Q4 2025 | -0.1x | Net Cash |
| Q3 2025 | -0.1x | Net Cash |
| Q2 2025 | -0.0x | Net Cash |
| Q1 2025 | -0.1x | Net Cash |
| Q4 2024 | -0.2x | Net Cash |
AMZN has the edge over MNRO on leverage, with a lower net debt burden relative to earnings.
MNRO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.5x | Healthy |
| Q2 2026 | 1.5x | Healthy |
| Q1 2026 | 1.0x | Healthy |
| Q4 2025 | 1.2x | Healthy |
| Q3 2025 | 1.5x | Healthy |
| Q2 2025 | 1.7x | Healthy |
| Q1 2025 | 1.0x | Very low |
| Q4 2024 | 0.8x | Very low |
MNRO's net debt is about 1.5 years of its operating earnings (EBITDA), about the same as a year ago.
AMZN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 57.1 | Neutral |
| Stochastic | 50.0 | Neutral |
AMZN's weekly RSI is 57 (neutral) and its Stochastic is 50 (neutral).
MNRO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.0 | Neutral |
| Stochastic | 5.4 | Oversold |
MNRO's weekly RSI is 34 (neutral) and its Stochastic is 5 (oversold).
AMZN PE vs Consumer Cyclical Sector
| Metric | AMZN | Sector median | Relative |
|---|---|---|---|
| PE | 22x | 18x | 20% above |
| PE % | 4 | 47 | 43 pts below |
AMZN has the edge over MNRO on valuation relative to its sector.
MNRO PE vs Consumer Cyclical Sector
| Metric | MNRO | Sector median | Relative |
|---|---|---|---|
| PE | 58x | 18x | 219% above |
| PE % | 85 | 47 | 38 pts above |
MNRO has no meaningful PE right now: it lost money over the past year.
AMZN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $253.6 | 5.5% above |
| 20 week MA | $254.9 | 4.9% above |
| 50 week MA | $242.5 | 10% above |
| 100 week MA | $229.6 | 17% above |
| 200 week MA | $191.4 | 40% above |
AMZN has the edge over MNRO on trend strength, trading above more of its moving averages.
MNRO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $12.7 | 18% below |
| 20 week MA | $13.5 | 23% below |
| 50 week MA | $16.4 | 37% below |
| 100 week MA | $16.8 | 38% below |
| 200 week MA | $25.1 | 59% below |
MNRO is in a downtrend: it's below all five of its weekly moving averages, and 59% below its 200-week average.
AMZN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $93.5 | $158.6 | +70% |
| 2021 | $158.6 | $171.1 | +7.8% |
| 2022 | $171.1 | $85.3 | -50% |
| 2023 | $85.3 | $151.9 | +78% |
| 2024 | $151.9 | $223.8 | +47% |
| 2025 | $223.8 | $232.5 | +3.9% |
| 2026 YTD | $232.5 | $267.4 | +15% |
AMZN has the edge over MNRO on returns for 2026, with the stronger performance.
MNRO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $78.9 | $53.1 | -33% |
| 2021 | $53.1 | $59.2 | +11% |
| 2022 | $59.2 | $45.2 | -24% |
| 2023 | $45.2 | $29.3 | -35% |
| 2024 | $29.3 | $24.8 | -16% |
| 2025 | $24.8 | $20.8 | -16% |
| 2026 YTD | $20.8 | $10.4 | -50% |
MNRO has finished four years in a row lower, and it's down 50% so far in 2026.